Review Article
Application of New Biotechnologies for Prostate Cancer Treatment (Comparative Analysis of Brachytherapy, Cryosurgery, Laparoscopy, Robotic Arm and Cyberknife Methods)
Giuseppe Morgia*, Chaled Alnakib, Giorgio Ivan Russo | |
Department of Urology, University of Catania, Italy | |
Corresponding Author : | Giuseppe Morgia Professor, Department of Urology University of Catania, Italy E-mail: gmorgia@policlinico.unict.it |
Received June 26, 2013; Accepted September 26, 2013; Published September 28, 2013 | |
Citation: Morgia G, Alnakib C, Russo GI (2013) Application of New Biotechnologies for Prostate Cancer Treatment (Comparative Analysis of Brachytherapy, Cryosurgery, Laparoscopy, Robotic Arm and Cyberknife Methods). Clin Pharmacol Biopharm 2:113. doi:10.4172/2167-065X.1000113 | |
Copyright: © 2013 Morgia G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
Abstract
Prostate cancer is the second most commonly diagnosed non-dermatologic malignancy among American men and the 6th most fatal cancer worldwide. Open field radical prostatectomy is the gold standard procedure for treatment of prostate cancer. Yet, several novel methodologies have been emerging lately, promising to be mini-invasive, to reduce complications related to surgery and to offer the patient a better quality of life thereafter. Among the latter, preservation of urinary and sexual function appear to be the most important. Some of such alternative treatments may be found applicable to patients with a life expectancy less than 10 years, or those unfit for surgery for other reasons. The present manuscript has been aimed to overview the most prominent novel methods for prostate cancer treatment, in attempt to point out the options and the rationale for choosing a method, or a combination of methods, for the best and the most effective treatment of prostate cancer.